#ESMO26 | LBA1 – INTerpath-001
✅ First positive Phase 3 of individualized mRNA neoantigen therapy in adjuvant melanoma
Intismeran autogene + pembrolizumab vs pembrolizumab alone
(Resected stage IIB–IV | N=1,137 | median FU 24.6 mo)
✅ RFS: HR 0.58 (0.45–0.75) | p<0.001
→ 24-mo RFS 82.2% vs 70.0%
✅ DMFS: HR 0.62 (0.45–0.85) | p=0.002
→ 24-mo DMFS 88.5% vs 80.2%
✅ Benefit across most subgroups
✅ Manageable safety (no potentiation of pembro AEs)
✅ OS still immature
New benchmark for adjuvant melanoma.
Presented by Georgina V. Long
#ESMO26 #Melanoma #mRNA #INTerpath001 @myESMO @OncoAlert